Vasoactive Intestinal Peptide - Explore the Science & Experts | ideXlab

Scan Science and Technology

Contact Leading Edge Experts & Companies

Vasoactive Intestinal Peptide

The Experts below are selected from a list of 216 Experts worldwide ranked by ideXlab platform

Vasoactive Intestinal Peptide – Free Register to Access Experts & Abstracts

Xinguo Jiang – One of the best experts on this subject based on the ideXlab platform.

Hongzhuan Chen – One of the best experts on this subject based on the ideXlab platform.

  • brain delivery of Vasoactive Intestinal Peptide enhanced with the nanoparticles conjugated with wheat germ agglutinin following intranasal administration
    Journal of Controlled Release, 2007
    Co-Authors: Bingxian Wu, Qizhi Zhang, Jun Chen, Weiwei Zhang, Zhengxin Rong, Hongzhuan Chen, Xinguo Jiang
    Abstract:

    Abstracts The development of biotech drugs such as Peptides and proteins that act in the central nervous system has been significantly impeded by the difficulty of delivering them across the blood-brain barrier. The surface engineering of nanoparticles with lectins opened a novel pathway to the absorption of drugs loaded by biodegradable poly (ethylene glycol)-poly (lactic acid) nanoparticles in the brain following intranasal administration. In the present study, Vasoactive Intestinal Peptide, a neuroprotective Peptide, was efficiently incorporated into the poly (ethylene glycol)-poly (lactic acid) nanoparticles modified with wheat germ agglutinin and the biodistribution, brain uptake and neuroprotective effect of the formulation were assessed. The area under the concentration-time curve of intact 125I-Vasoactive Intestinal Peptide in brain of mice following the intranasal administration of 125I-Vasoactive Intestinal Peptide carried by nanoparticles and wheat germ agglutinin-conjugated ones was significantly enlarged by 3.5 ∼ 4.7 folds and 5.6 ∼ 7.7 folds, respectively, compared with that after intranasal application of 125I-Vasoactive Intestinal Peptide solution. The same improvements in spatial memory in ethylcholine aziridium-treated rats were observed following intranasal administration of 25 μg/kg and 12.5 μg/kg of Vasoactive Intestinal Peptide loaded by unmodified nanoparticles and wheat germ agglutinin-modified nanoparticles, respectively. Distribution profiles of wheat germ agglutinin-conjugated nanoparticles in the nasal cavity presented their higher affinity to the olfactory mucosa than to the respiratory one. Inhibition experiment with specific sugars suggested that the interaction between the nasal mucosa and the wheat germ agglutinin-functionalized nanoparticles were due to the immobilization of carbohydrate-binding pockets on the surface of the nanoparticles. The results clearly indicated wheat germ agglutinin-modified nanoparticles might serve as promising carriers especially for biotech drugs such as Peptides and proteins.

  • brain delivery of Vasoactive Intestinal Peptide enhanced with the nanoparticles conjugated with wheat germ agglutinin following intranasal administration
    Journal of Controlled Release, 2007
    Co-Authors: Xiaoling Gao, Qizhi Zhang, Jun Chen, Weiwei Zhang, Zhengxin Rong, Hongzhuan Chen, Jianhua Zhu, Xinguo Jiang
    Abstract:

    The development of biotech drugs such as Peptides and proteins that act in the central nervous system has been significantly impeded by the difficulty of delivering them across the blood-brain barrier. The surface engineering of nanoparticles with lectins opened a novel pathway to the absorption of drugs loaded by biodegradable poly (ethylene glycol)-poly (lactic acid) nanoparticles in the brain following intranasal administration. In the present study, Vasoactive Intestinal Peptide, a neuroprotective Peptide, was efficiently incorporated into the poly (ethylene glycol)-poly (lactic acid) nanoparticles modified with wheat germ agglutinin and the biodistribution, brain uptake and neuroprotective effect of the formulation were assessed. The area under the concentration-time curve of intact 125I-Vasoactive Intestinal Peptide in brain of mice following the intranasal administration of 125I-Vasoactive Intestinal Peptide carried by nanoparticles and wheat germ agglutinin-conjugated ones was significantly enlarged by 3.5 approximately 4.7 folds and 5.6 approximately 7.7 folds, respectively, compared with that after intranasal application of 125I-Vasoactive Intestinal Peptide solution. The same improvements in spatial memory in ethylcholine aziridium-treated rats were observed following intranasal administration of 25 microg/kg and 12.5 microg/kg of Vasoactive Intestinal Peptide loaded by unmodified nanoparticles and wheat germ agglutinin-modified nanoparticles, respectively. Distribution profiles of wheat germ agglutinin-conjugated nanoparticles in the nasal cavity presented their higher affinity to the olfactory mucosa than to the respiratory one. Inhibition experiment with specific sugars suggested that the interaction between the nasal mucosa and the wheat germ agglutinin-functionalized nanoparticles were due to the immobilization of carbohydrate-binding pockets on the surface of the nanoparticles. The results clearly indicated wheat germ agglutinin-modified nanoparticles might serve as promising carriers especially for biotech drugs such as Peptides and proteins.

Zhengxin Rong – One of the best experts on this subject based on the ideXlab platform.

  • brain delivery of Vasoactive Intestinal Peptide enhanced with the nanoparticles conjugated with wheat germ agglutinin following intranasal administration
    Journal of Controlled Release, 2007
    Co-Authors: Bingxian Wu, Qizhi Zhang, Jun Chen, Weiwei Zhang, Zhengxin Rong, Hongzhuan Chen, Xinguo Jiang
    Abstract:

    Abstracts The development of biotech drugs such as Peptides and proteins that act in the central nervous system has been significantly impeded by the difficulty of delivering them across the blood-brain barrier. The surface engineering of nanoparticles with lectins opened a novel pathway to the absorption of drugs loaded by biodegradable poly (ethylene glycol)-poly (lactic acid) nanoparticles in the brain following intranasal administration. In the present study, Vasoactive Intestinal Peptide, a neuroprotective Peptide, was efficiently incorporated into the poly (ethylene glycol)-poly (lactic acid) nanoparticles modified with wheat germ agglutinin and the biodistribution, brain uptake and neuroprotective effect of the formulation were assessed. The area under the concentration-time curve of intact 125I-Vasoactive Intestinal Peptide in brain of mice following the intranasal administration of 125I-Vasoactive Intestinal Peptide carried by nanoparticles and wheat germ agglutinin-conjugated ones was significantly enlarged by 3.5 ∼ 4.7 folds and 5.6 ∼ 7.7 folds, respectively, compared with that after intranasal application of 125I-Vasoactive Intestinal Peptide solution. The same improvements in spatial memory in ethylcholine aziridium-treated rats were observed following intranasal administration of 25 μg/kg and 12.5 μg/kg of Vasoactive Intestinal Peptide loaded by unmodified nanoparticles and wheat germ agglutinin-modified nanoparticles, respectively. Distribution profiles of wheat germ agglutinin-conjugated nanoparticles in the nasal cavity presented their higher affinity to the olfactory mucosa than to the respiratory one. Inhibition experiment with specific sugars suggested that the interaction between the nasal mucosa and the wheat germ agglutinin-functionalized nanoparticles were due to the immobilization of carbohydrate-binding pockets on the surface of the nanoparticles. The results clearly indicated wheat germ agglutinin-modified nanoparticles might serve as promising carriers especially for biotech drugs such as Peptides and proteins.

  • brain delivery of Vasoactive Intestinal Peptide enhanced with the nanoparticles conjugated with wheat germ agglutinin following intranasal administration
    Journal of Controlled Release, 2007
    Co-Authors: Xiaoling Gao, Qizhi Zhang, Jun Chen, Weiwei Zhang, Zhengxin Rong, Hongzhuan Chen, Jianhua Zhu, Xinguo Jiang
    Abstract:

    The development of biotech drugs such as Peptides and proteins that act in the central nervous system has been significantly impeded by the difficulty of delivering them across the blood-brain barrier. The surface engineering of nanoparticles with lectins opened a novel pathway to the absorption of drugs loaded by biodegradable poly (ethylene glycol)-poly (lactic acid) nanoparticles in the brain following intranasal administration. In the present study, Vasoactive Intestinal Peptide, a neuroprotective Peptide, was efficiently incorporated into the poly (ethylene glycol)-poly (lactic acid) nanoparticles modified with wheat germ agglutinin and the biodistribution, brain uptake and neuroprotective effect of the formulation were assessed. The area under the concentration-time curve of intact 125I-Vasoactive Intestinal Peptide in brain of mice following the intranasal administration of 125I-Vasoactive Intestinal Peptide carried by nanoparticles and wheat germ agglutinin-conjugated ones was significantly enlarged by 3.5 approximately 4.7 folds and 5.6 approximately 7.7 folds, respectively, compared with that after intranasal application of 125I-Vasoactive Intestinal Peptide solution. The same improvements in spatial memory in ethylcholine aziridium-treated rats were observed following intranasal administration of 25 microg/kg and 12.5 microg/kg of Vasoactive Intestinal Peptide loaded by unmodified nanoparticles and wheat germ agglutinin-modified nanoparticles, respectively. Distribution profiles of wheat germ agglutinin-conjugated nanoparticles in the nasal cavity presented their higher affinity to the olfactory mucosa than to the respiratory one. Inhibition experiment with specific sugars suggested that the interaction between the nasal mucosa and the wheat germ agglutinin-functionalized nanoparticles were due to the immobilization of carbohydrate-binding pockets on the surface of the nanoparticles. The results clearly indicated wheat germ agglutinin-modified nanoparticles might serve as promising carriers especially for biotech drugs such as Peptides and proteins.

Weiwei Zhang – One of the best experts on this subject based on the ideXlab platform.

  • brain delivery of Vasoactive Intestinal Peptide enhanced with the nanoparticles conjugated with wheat germ agglutinin following intranasal administration
    Journal of Controlled Release, 2007
    Co-Authors: Bingxian Wu, Qizhi Zhang, Jun Chen, Weiwei Zhang, Zhengxin Rong, Hongzhuan Chen, Xinguo Jiang
    Abstract:

    Abstracts The development of biotech drugs such as Peptides and proteins that act in the central nervous system has been significantly impeded by the difficulty of delivering them across the blood-brain barrier. The surface engineering of nanoparticles with lectins opened a novel pathway to the absorption of drugs loaded by biodegradable poly (ethylene glycol)-poly (lactic acid) nanoparticles in the brain following intranasal administration. In the present study, Vasoactive Intestinal Peptide, a neuroprotective Peptide, was efficiently incorporated into the poly (ethylene glycol)-poly (lactic acid) nanoparticles modified with wheat germ agglutinin and the biodistribution, brain uptake and neuroprotective effect of the formulation were assessed. The area under the concentration-time curve of intact 125I-Vasoactive Intestinal Peptide in brain of mice following the intranasal administration of 125I-Vasoactive Intestinal Peptide carried by nanoparticles and wheat germ agglutinin-conjugated ones was significantly enlarged by 3.5 ∼ 4.7 folds and 5.6 ∼ 7.7 folds, respectively, compared with that after intranasal application of 125I-Vasoactive Intestinal Peptide solution. The same improvements in spatial memory in ethylcholine aziridium-treated rats were observed following intranasal administration of 25 μg/kg and 12.5 μg/kg of Vasoactive Intestinal Peptide loaded by unmodified nanoparticles and wheat germ agglutinin-modified nanoparticles, respectively. Distribution profiles of wheat germ agglutinin-conjugated nanoparticles in the nasal cavity presented their higher affinity to the olfactory mucosa than to the respiratory one. Inhibition experiment with specific sugars suggested that the interaction between the nasal mucosa and the wheat germ agglutinin-functionalized nanoparticles were due to the immobilization of carbohydrate-binding pockets on the surface of the nanoparticles. The results clearly indicated wheat germ agglutinin-modified nanoparticles might serve as promising carriers especially for biotech drugs such as Peptides and proteins.

  • brain delivery of Vasoactive Intestinal Peptide enhanced with the nanoparticles conjugated with wheat germ agglutinin following intranasal administration
    Journal of Controlled Release, 2007
    Co-Authors: Xiaoling Gao, Qizhi Zhang, Jun Chen, Weiwei Zhang, Zhengxin Rong, Hongzhuan Chen, Jianhua Zhu, Xinguo Jiang
    Abstract:

    The development of biotech drugs such as Peptides and proteins that act in the central nervous system has been significantly impeded by the difficulty of delivering them across the blood-brain barrier. The surface engineering of nanoparticles with lectins opened a novel pathway to the absorption of drugs loaded by biodegradable poly (ethylene glycol)-poly (lactic acid) nanoparticles in the brain following intranasal administration. In the present study, Vasoactive Intestinal Peptide, a neuroprotective Peptide, was efficiently incorporated into the poly (ethylene glycol)-poly (lactic acid) nanoparticles modified with wheat germ agglutinin and the biodistribution, brain uptake and neuroprotective effect of the formulation were assessed. The area under the concentration-time curve of intact 125I-Vasoactive Intestinal Peptide in brain of mice following the intranasal administration of 125I-Vasoactive Intestinal Peptide carried by nanoparticles and wheat germ agglutinin-conjugated ones was significantly enlarged by 3.5 approximately 4.7 folds and 5.6 approximately 7.7 folds, respectively, compared with that after intranasal application of 125I-Vasoactive Intestinal Peptide solution. The same improvements in spatial memory in ethylcholine aziridium-treated rats were observed following intranasal administration of 25 microg/kg and 12.5 microg/kg of Vasoactive Intestinal Peptide loaded by unmodified nanoparticles and wheat germ agglutinin-modified nanoparticles, respectively. Distribution profiles of wheat germ agglutinin-conjugated nanoparticles in the nasal cavity presented their higher affinity to the olfactory mucosa than to the respiratory one. Inhibition experiment with specific sugars suggested that the interaction between the nasal mucosa and the wheat germ agglutinin-functionalized nanoparticles were due to the immobilization of carbohydrate-binding pockets on the surface of the nanoparticles. The results clearly indicated wheat germ agglutinin-modified nanoparticles might serve as promising carriers especially for biotech drugs such as Peptides and proteins.

Jun Chen – One of the best experts on this subject based on the ideXlab platform.

  • brain delivery of Vasoactive Intestinal Peptide enhanced with the nanoparticles conjugated with wheat germ agglutinin following intranasal administration
    Journal of Controlled Release, 2007
    Co-Authors: Bingxian Wu, Qizhi Zhang, Jun Chen, Weiwei Zhang, Zhengxin Rong, Hongzhuan Chen, Xinguo Jiang
    Abstract:

    Abstracts The development of biotech drugs such as Peptides and proteins that act in the central nervous system has been significantly impeded by the difficulty of delivering them across the blood-brain barrier. The surface engineering of nanoparticles with lectins opened a novel pathway to the absorption of drugs loaded by biodegradable poly (ethylene glycol)-poly (lactic acid) nanoparticles in the brain following intranasal administration. In the present study, Vasoactive Intestinal Peptide, a neuroprotective Peptide, was efficiently incorporated into the poly (ethylene glycol)-poly (lactic acid) nanoparticles modified with wheat germ agglutinin and the biodistribution, brain uptake and neuroprotective effect of the formulation were assessed. The area under the concentration-time curve of intact 125I-Vasoactive Intestinal Peptide in brain of mice following the intranasal administration of 125I-Vasoactive Intestinal Peptide carried by nanoparticles and wheat germ agglutinin-conjugated ones was significantly enlarged by 3.5 ∼ 4.7 folds and 5.6 ∼ 7.7 folds, respectively, compared with that after intranasal application of 125I-Vasoactive Intestinal Peptide solution. The same improvements in spatial memory in ethylcholine aziridium-treated rats were observed following intranasal administration of 25 μg/kg and 12.5 μg/kg of Vasoactive Intestinal Peptide loaded by unmodified nanoparticles and wheat germ agglutinin-modified nanoparticles, respectively. Distribution profiles of wheat germ agglutinin-conjugated nanoparticles in the nasal cavity presented their higher affinity to the olfactory mucosa than to the respiratory one. Inhibition experiment with specific sugars suggested that the interaction between the nasal mucosa and the wheat germ agglutinin-functionalized nanoparticles were due to the immobilization of carbohydrate-binding pockets on the surface of the nanoparticles. The results clearly indicated wheat germ agglutinin-modified nanoparticles might serve as promising carriers especially for biotech drugs such as Peptides and proteins.

  • brain delivery of Vasoactive Intestinal Peptide enhanced with the nanoparticles conjugated with wheat germ agglutinin following intranasal administration
    Journal of Controlled Release, 2007
    Co-Authors: Xiaoling Gao, Qizhi Zhang, Jun Chen, Weiwei Zhang, Zhengxin Rong, Hongzhuan Chen, Jianhua Zhu, Xinguo Jiang
    Abstract:

    The development of biotech drugs such as Peptides and proteins that act in the central nervous system has been significantly impeded by the difficulty of delivering them across the blood-brain barrier. The surface engineering of nanoparticles with lectins opened a novel pathway to the absorption of drugs loaded by biodegradable poly (ethylene glycol)-poly (lactic acid) nanoparticles in the brain following intranasal administration. In the present study, Vasoactive Intestinal Peptide, a neuroprotective Peptide, was efficiently incorporated into the poly (ethylene glycol)-poly (lactic acid) nanoparticles modified with wheat germ agglutinin and the biodistribution, brain uptake and neuroprotective effect of the formulation were assessed. The area under the concentration-time curve of intact 125I-Vasoactive Intestinal Peptide in brain of mice following the intranasal administration of 125I-Vasoactive Intestinal Peptide carried by nanoparticles and wheat germ agglutinin-conjugated ones was significantly enlarged by 3.5 approximately 4.7 folds and 5.6 approximately 7.7 folds, respectively, compared with that after intranasal application of 125I-Vasoactive Intestinal Peptide solution. The same improvements in spatial memory in ethylcholine aziridium-treated rats were observed following intranasal administration of 25 microg/kg and 12.5 microg/kg of Vasoactive Intestinal Peptide loaded by unmodified nanoparticles and wheat germ agglutinin-modified nanoparticles, respectively. Distribution profiles of wheat germ agglutinin-conjugated nanoparticles in the nasal cavity presented their higher affinity to the olfactory mucosa than to the respiratory one. Inhibition experiment with specific sugars suggested that the interaction between the nasal mucosa and the wheat germ agglutinin-functionalized nanoparticles were due to the immobilization of carbohydrate-binding pockets on the surface of the nanoparticles. The results clearly indicated wheat germ agglutinin-modified nanoparticles might serve as promising carriers especially for biotech drugs such as Peptides and proteins.